Literature DB >> 17131342

Identification of HLA-A24 restricted shared antigen recognized by autologous cytotoxic T lymphocytes from a patient with large cell carcinoma of the lung.

Masakazu Sugaya1, Mitsuhiro Takenoyama, Yoshiki Shigematsu, Tetsuro Baba, Takashi Fukuyama, Yoshika Nagata, Makiko Mizukami, Tetsuya So, Yoshinobu Ichiki, Manabu Yasuda, Tomoko So, Takeshi Hanagiri, Kenji Sugio, Kosei Yasumoto.   

Abstract

The aim of the present study was to elucidate the tumor-specific cellular immunological responses occurring in a patient with large cell carcinoma of the lung who had no evidence of recurrence following surgical resections of both a primary lung lesion and a metastatic adrenal lesion. We analyzed an autologous tumor-specific cytotoxic T lymphocytes (CTL clone F2b), which were HLA-A*2402 restricted from regional lymph node lymphocytes. The F2b possessed T cell receptor (TCR) using the Valpha5 and Vbeta7 gene segment. The existence of precursor CTL (pCTL) against autologous tumor cells (A904L) was analyzed using CTL clone-specific PCR. Lymphocytes with the same TCR as F2b were detected in the primary tumor tissue, regional lymph node and the peripheral blood collected from the patient 3 years after the operation. Using the F2b, we identified a cDNA clone encoding the tumor antigen using cDNA expression cloning method. The gene was found to encode splicing variant of the Tara gene. Finally, we identified the 9-mer Ag peptide, using constructions of mini-genes. The F2b recognized 3 out of 7 HLA-A24 positive allogeneic tumor cell lines and in 1 out of 7 HLA-A24 negative allogeneic tumor cell lines when transfected with HLA-A24. This peptide is therefore considered to be potentially useful for performing specific immunotherapy in a significant proportion of lung cancer patients bearing HLA-A24. Copyright 2006 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17131342     DOI: 10.1002/ijc.22396

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  4 in total

1.  Antitumor activity of human γδ T cells transducted with CD8 and with T-cell receptors of tumor-specific cytotoxic T lymphocytes.

Authors:  Takeshi Hanagiri; Yoshiki Shigematsu; Koji Kuroda; Tetsuro Baba; Hironobu Shiota; Yoshinobu Ichiki; Yoshika Nagata; Manabu Yasuda; Tomoko So; Mitsuhiro Takenoyama; Fumihiro Tanaka
Journal:  Cancer Sci       Date:  2012-07-06       Impact factor: 6.716

2.  Differences in sensitivity to tumor-specific CTLs between primary and metastatic esophageal cancer cell lines derived from the same patient.

Authors:  Yoshinobu Ichiki; Takeshi Hanagiri; Mitsuhiro Takenoyama; Tetsuro Baba; Yoshika Nagata; Makiko Mizukami; Tetsuya So; Masakazu Sugaya; Manabu Yasuda; Hidetaka Uramoro; Kosei Yasumoto
Journal:  Surg Today       Date:  2012-01-12       Impact factor: 2.549

Review 3.  Lung cancer-associated tumor antigens and the present status of immunotherapy against non-small-cell lung cancer.

Authors:  Kosei Yasumoto; Takeshi Hanagiri; Mitsuhiro Takenoyama
Journal:  Gen Thorac Cardiovasc Surg       Date:  2009-09-13

4.  Development of adoptive immunotherapy with KK-LC-1-specific TCR-transduced γδT cells against lung cancer cells.

Authors:  Yoshinobu Ichiki; Yoshiki Shigematsu; Tetsuro Baba; Hironobu Shiota; Takashi Fukuyama; Yoshika Nagata; Tetsuya So; Manabu Yasuda; Mitsuhiro Takenoyama; Kosei Yasumoto
Journal:  Cancer Sci       Date:  2020-09-16       Impact factor: 6.716

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.